Key Points
- CEO Joseph Oliveto sold 43,000 shares on Jan. 8 at an average price of $2.25 for proceeds of $96,750, trimming his holding by 12.40% to 303,721 shares (≈$683,372).
- NASDAQ:MIST opened at $2.04, trades in a 12‑month range of $0.63–$3.06, has a market cap of about $173.8 million and a negative trailing P/E (–2.49), with 50‑ and 200‑day moving averages near $2.23 and $1.96.
- Analysts are mixed but leaning positive—four Buy, one Hold, one Sell—with a consensus target of $8.00, and institutional investors own roughly 86.18% of the stock amid recent hedge fund buying.
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 43,000 shares of the business's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $2.25, for a total value of $96,750.00. Following the transaction, the chief executive officer directly owned 303,721 shares in the company, valued at approximately $683,372.25. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Joseph Oliveto also recently made the following trade(s):
- On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total value of $1,125.00.
Milestone Pharmaceuticals Stock Performance
Shares of NASDAQ MIST opened at $2.04 on Friday. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. The company has a market capitalization of $173.75 million, a P/E ratio of -2.49 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $3.06. The stock has a 50 day moving average of $2.23 and a 200-day moving average of $1.96.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. As a group, equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "buy" rating and set a $8.00 price objective for the company in a research report on Monday, December 15th. Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an "overweight" rating in a research report on Tuesday, December 16th. Wall Street Zen lowered Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Cowen raised Milestone Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Monday, December 15th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $8.00.
Get Our Latest Report on MIST
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth $197,000. Bay Rivers Group lifted its holdings in shares of Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company's stock worth $58,000 after acquiring an additional 12,170 shares during the last quarter. Millennium Management LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth about $803,000. Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at approximately $1,333,000. Finally, Bank of America Corp DE grew its holdings in shares of Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company's stock valued at $32,000 after purchasing an additional 16,044 shares during the last quarter. 86.18% of the stock is owned by institutional investors.
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.
Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
